首页> 外文期刊>Arquivos de Neuro-Psiquiatria >Naproxen sodium decreases migraine recurrence when administered with sumatriptan
【24h】

Naproxen sodium decreases migraine recurrence when administered with sumatriptan

机译:萘普生钠与舒马普坦合用可降低偏头痛的复发

获取原文
           

摘要

Forty to 78% of the patients using sumatriptan for the acute treatment of migraine may present recurrence at least occasionally. The concomitant use of a NSAID (nonsteroidal anti-inflammatory drug) has been recommended to decrease the recurrence rate. Sixty seven patients that treated successfully 8 migraine attacks with 100 mg of sumatritpan PO and presented recurrence in at least 5 attacks were studied prospectively. The patients received 100 mg of sumatriptan and 550 mg of naproxen sodium PO to treat 4 consecutive moderate or severe migraine attacks. The recurrence rate, once at least 62.5% (5 out of 8 attacks), decreased to 14.2% (38 out of 268 attacks) with the combination of compounds (p
机译:使用舒马曲坦进行偏头痛急性治疗的患者中有40%至78%至少偶尔会出现复发。建议同时使用NSAID(非甾体类抗炎药)以降低复发率。前瞻性研究了67例患者,这些患者成功地用100 mg sumatritpan PO治疗了8次偏头痛发作,并在至少5次发作中复发。患者接受100 mg舒马曲坦和550 mg萘普生钠PO的治疗,以治疗4次连续的中度或重度偏头痛发作。至少有62.5%的复发率(8次发作中的5次),通过化合物的组合,复发率降至14.2%(268次发作中的38次)(p

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号